the best shares

We’re heading into some lighter trading days with the Thanksgiving holiday and the official opening of the Holiday Shopping season. Today’s Three Big Stock Charts looks at a few stocks that have gone parabolic in the month of November and asks “can these stocks go higher?”

Three stocks that are on our “Rocket List” are Best Buy Co Inc (NYSE:BBY), Darden Restaurants, Inc. (NYSE:DRI) and Automatic Data Processing (NASDAQ:ADP), as each of these companies have taken the recent rally to the next level by going parabolic in their ascent.

Best Buy Co Inc (BBY)

the best shares: General Motors Company(GM)

Advisors’ Opinion:

  • [By Paul Ausick]

    General Motors Co. (NYSE: GM) on Friday posted total November U.S. sales of 245,387 vehicles, a decrease of 2.9% compared with November 2016. Retail deliveries dropped 0.1% in the month to 197,340 units, and fleet deliveries rose to 19.6% for the month. Fleet sales now account for 19.4% of 2017 sales.

  • [By Shanthi Rexaline]

    Should General Motors Company (NYSE: GM) split its stock? According to David Einhorn-founded hedge fund Greenlight Capital in a recent presentation, there’s a case for two classes of GM shares to unlock value.

  • [By Michael A. Robinson]

    I recommended Mobileye to you folks on March 31, 2015. I noted that many automakers – Audi AG, Ford Motor Co. (NYSE: F), General Motors Co. (NYSE: GM), Tesla Inc. (Nasdaq: TSLA), and Volvo AB among them – had turned over the keys of their driverless vehicle programs to Mobileye.

  • [By Laurie Kulikowski]

    Even after a recent rally, GM still trades at just 3.1x NTM EBITDAPO, a discount to the low-end of our sense of its normalized historical trading range of roughly 3.5x to 4.5x, despite significant structural improvements in the North American automotive industry and the company, which in our view argue for a premium to history. Auto parts suppliers, for example, trade at material premiums to history (7.0x NTM EBITDAP vs. 5.3x long-run average), largely given the improvements at OEMs such as General Motors, which have made for a structurally healthier and more profitable industry for all market participants. We note GM also sports a 4.0% dividend yield, making it attractive to income oriented investors, and yields 8.5% free cash flow to equity, on our 2016 estimates. GM has another $2.1 billion remaining on a repurchase program management intends to complete by 2016-end, equating to another 4% of shares outstanding (on top of the over 5% repurchased to date). 

the best shares: Sunoco LP(SUN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).

  • [By Lisa Levin]

    Thursday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).

  • [By Douglas A. McIntyre]

    Exxon Mobil Corp. (NYSE: XOM) is the second largest company in America and the world’s largest oil company. Chevron Corp. (NYSE: CVX) is the third largest company in the United States. Valero Corp. (NYSE: VLO) is among the world’s largest refiners. Sunoco L.P. (NYSE: SUN) is one of North America’s largest owners of stations and convenience stores. BP PLC (NYSE: BP) is among the world’s oil behemoths. Shell is the U.S. branch of oil giant Royal Dutch Shell PLC (NYSE: RDS-A).

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on August 3, 2016.

    J B Hunt Transport Services Inc (NASDAQ: JBHT) – $0.2200 dividend, 1.0791 percent yield
    Johnson Controls Inc (NYSE: JCI) – $0.2900 dividend, 2.6250 percent yield
    FirstEnergy Corp. (NYSE: FE) – $0.3600 dividend, 3.9680 percent yield
    Sunoco LP (NYSE: SUN) – $0.8255 dividend, 10.7347 percent yield
    Wells Fargo & Co (NYSE: WFC) – $0.3800 dividend, 3.1588 percent yield
    BP plc (ADR) (NYSE: BP) – $0.6000 dividend, 6.8768 percent yield
    American Airlines Group Inc (NASDAQ: AAL) – $0.1000 dividend, 1.1442 percent yield
    Heidrick & Struggles International, Inc. (NASDAQ: HSII) – $0.1300 dividend, 2.9834 percent yield
    Alcoa Inc (NYSE: AA) – $0.0300 dividend, 1.1321 percent yield
    Sensient Technologies Corporation (NYSE: SXT) – $0.2700 dividend, 1.5341 percent yield

    Posted-In: Ex-DividendNews Dividends Markets Trading Ideas

the best shares: Preferred Bank(PFBC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Preferred Bank (PFBC) has surged 54% in the past year but still trades at a modest discount to the median S&P 1500 regional bank, based on both trailing earnings and estimated 2017 profits.

the best shares: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

Leave a Reply

Your email address will not be published. Required fields are marked *